Prostate cancer with homologous recombination repair gene mutations and PARP inhibitors: clinical progress
10.3760/cma.j.cn112330-20201117-00777
- VernacularTitle:PARP抑制剂在同源重组修复基因突变型前列腺癌中的临床研究进展
- Author:
Yao ZHU
;
Yu WEI
;
Jian PAN
;
Bangwei FANG
;
Dingwei YE
- From:
Chinese Journal of Urology
2021;42(5):397-400
- CountryChina
- Language:Chinese
-
Abstract:
DNA damage repair gene mutations are prevalent in advanced prostate cancer. Among these, mutations in homologous recombination repair genes could impair the ability of cell to restore the DNA double-strand break, which can be exploited by Poly-ADP-ribose polymerase (PARP) inhibitors through synthetic lethality and result in cell death. The phase Ⅲ study " PROfound" showed that the PAPR inhibitor Olaparib could significantly improve the survival of patients with homologous recombination repair gene mutations compared with novel hormone agents, starting the era of targeted, precise and individualized treatment based on genetic profile detection for prostate cancer treatment.
